

# **Integrated Filing (Finance) Ind AS**

## **Orchid Pharma Limited**

### **General Information**

Scrip code*	524372
NSE Symbol*	ORCHPHARMA
MSEI Symbol*	NOTLISTED
ISIN*	INE191A01027
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	11-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-11-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical
Start date of board meeting	11-11-2025
Start time of board meeting	12:00:00
End date of board meeting	11-11-2025
End time of board meeting	15:00:00
Whether cash flow statement is applicable on company	true
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

## Financial Results - Ind-AS

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
1	<b>Income</b>		
	Revenue from operations	19,352.42	36,645.30
	Other income	1,077.44	2,222.20
	<b>Total income</b>	20,429.86	38,867.50
2	<b>Expenses</b>		
(a)	Cost of materials consumed	11,226.77	22,242.51
(b)	Purchases of stock-in-trade	17.34	96.13
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,006.54	798.55
(d)	Employee benefit expense	2,485.06	4,646.35
(e)	Finance costs	373.23	698.98
(f)	Depreciation, depletion and amortisation expense	890.14	1,755.55
(g)	<b>Other Expenses</b>		
1	Other Expenses	3,764.27	7,591.80
	<b>Total other expenses</b>	3,764.27	7,591.80
	<b>Total expenses</b>	20,763.35	37,829.87
3	<b>Total profit before exceptional items and tax</b>	(333.49)	1,037.63
4	Exceptional items	0.00	0.00
5	<b>Total profit before tax</b>	(333.49)	1,037.63
6	<b>Tax expense</b>		
7	Current tax	0.00	0.00
8	Deferred tax	0.00	(14.83)
9	<b>Total tax expenses</b>	0.00	(14.83)
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	<b>Net Profit Loss for the period from continuing operations</b>	(333.49)	1,052.46
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	<b>Net profit (loss) from discontinued operation after tax</b>	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	(238.87)	(118.93)
16	<b>Total profit (loss) for period</b>	(572.36)	933.53
17	Other comprehensive income net of taxes	(39.45)	(54.93)

18	<b>Total Comprehensive Income for the period</b>	(611.81)	878.60
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	<b>Details of equity share capital</b>		
	Paid-up equity share capital	5,071.91	5,071.91
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	(1.13)	1.84
	Diluted earnings (loss) per share from continuing operations	(1.13)	1.84
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	(1.13)	1.84
	Diluted earnings (loss) per share from continuing and discontinued operations	(1.13)	1.84
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	<a href="#">Textual Information(1)</a>	

## Text Block

<a href="#">Textual Information(1)</a>	<p>1. The above results for the quarter and half year ended September 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on November 11, 2025. The statutory auditors of the company have expressed a modified conclusion on the Limited review. ' 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. ' 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. ' As on September 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : ' Statement of QIP Net Funds raised and utilisation ' Particulars Amount as stated in Total amount utilised Balance amount as on Remarks ' the Offer Document upto September 30, 2025 on September 30, 2025 kept ' Rs. In Lakhs, revised In Lakhs in Fixed Deposits Rs.in lakhs ' 1. Investment in OBPL, ' subsidiary, for setting up ' Jammu Manufacturing Facility 13500 7302 6198 ' 2. Repayment/prepayment, in ' full or in part, of certain ' outstanding borrowings ' availed by the company 19546 14100 5446 ' 3. Funding capital expenditure ' requirements for setting up a ' new block at the API facility ' of the Company in Alathur, ' Tamil Nadu 36 36 0 ' 4. General corporate purposes 6098 6372 0 ' Total 39180 27810 11644 ' ' As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on September 30, 2025. The allocation among the objects has been revised vide Shareholder Resolution dated September 20, 2025. ' Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. ' ' 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. ' 5. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited,</p>
--	---

the Amalgamating Company, with the ' Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, ' in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, ' giving No objection to the said amalgamation. ' The requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, During its hearing held on September 24, 2025, Honble NCLT issued directions to the Office of Official Liquidator and Regional Director to submit their report in the next hearing on November 26, 2025. he Report of Income tax department has already been filed. ' ' 6. The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH. Germany and Allecra Therapeutics SAS. France on October 29, 2025 and August 01, 2025 respectively. After the successful completion of above transactions. Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam, International Brand Name known as EXBLIFEP, known as OrbliceF in India, consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India back to India. ' ' 7. The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH. a Company incorporated under laws of Germany. now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. ' July 30, 2025. ' 8. Figures of the previous period have been regrouped or reclassified or restated wherever considered necessary.

## Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2025	01-04-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>		
<b>1 Amount of items that will not be reclassified to profit and loss</b>		
1 Items that will not be reclassified to profit and loss	(39.45)	(54.93)
Total Amount of items that will not be reclassified to profit and loss	(39.45)	(54.93)
2 Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
<b>3 Amount of items that will be reclassified to profit and loss</b>		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	(39.45)	(54.93)

## Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated
<b>Assets</b>	
<b>1 Non-current assets</b>	
Property, plant and equipment	61,505.69
Capital work-in-progress	12,031.76
Investment property	0.00
Goodwill	0.00
Other intangible assets	73.31
Intangible assets under development	1,483.17
Biological assets other than bearer plants	0.00
Investments accounted for using equity method	0.00
<b>Non-current financial assets</b>	
Non-current investments	4,850.81
Trade receivables, non-current	0.00
Loans, non-current	0.00
Other non-current financial assets	427.53
<b>Total non-current financial assets</b>	5,278.34
Deferred tax assets (net)	4,871.17
Other non-current assets	16,493.67
<b>Total non-current assets</b>	1,01,737.11
<b>2 Current assets</b>	
Inventories	30,622.05
<b>Current financial asset</b>	
Current investments	0.00
Trade receivables, current	20,217.27
Cash and cash equivalents	4,198.72
Bank balance other than cash and cash equivalents	10,651.61
Loans, current	0.00
Other current financial assets	107.31
<b>Total current financial assets</b>	35,174.91
Current tax assets (net)	198.94
Other current assets	4,446.91
<b>Total current assets</b>	70,442.81
3 Non-current assets classified as held for sale	0.00
4 Regulatory deferral account debit balances and related deferred tax Assets	24.95
<b>Total assets</b>	1,72,204.87
<b>Equity and liabilities</b>	
<b>1 Equity</b>	
<b>Equity attributable to owners of parent</b>	
Equity share capital	5,071.91
Other equity	1,22,312.42
<b>Total equity attributable to owners of parent</b>	1,27,384.33
Non controlling interest	

	<b>Total equity</b>	1,27,384.33
2	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	23,403.48
	<b>Trade payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	<b>Total Trade payable</b>	0.00
	Other non-current financial liabilities	0.00
	<b>Total non-current financial liabilities</b>	23,403.48
	Provisions, non-current	399.59
	Deferred tax liabilities (net)	0.00
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	0.00
	<b>Total non-current liabilities</b>	23,803.07
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	4,720.37
	<b>Trade payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	985.85
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	13,908.37
	<b>Total Trade payable</b>	14,894.22
	Other current financial liabilities	0.00
	<b>Total current financial liabilities</b>	19,614.59
	Other current liabilities	1,185.03
	Provisions, current	217.85
	Current tax liabilities (Net)	0.00
	Deferred government grants, Current	0.00
	<b>Total current liabilities</b>	21,017.47
3	Liabilities directly associated with assets in disposal group classified as held for sale	0.00
4	Regulatory deferral account credit balances and related deferred tax liability	0.00
	<b>Total liabilities</b>	44,820.54
	<b>Total equity and liabilities</b>	1,72,204.87
	Disclosure of notes on assets and liabilities	

## Cash flow statement indirect

Amount in (Lakhs)

Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated
<b>Part I</b>	
<b>Blue color marked fields are non-mandatory.</b>	
<b>1 Statement of cash flows</b>	
<b>Cash flows from used in operating activities</b>	
Profit before tax	1,037.63
<b>2 Adjustments for reconcile profit (loss)</b>	
Adjustments for finance costs	698.98
Adjustments for decrease (increase) in inventories	2,015.10
Adjustments for decrease (increase) in trade receivables, current	4,785.73
Adjustments for decrease (increase) in trade receivables, non-current	0.00
Adjustments for decrease (increase) in other current assets	929.44
Adjustments for decrease (increase) in other non-current assets	0.00
Adjustments for other financial assets, non-current	0.00
Adjustments for other financial assets, current	0.00
Adjustments for other bank balances	0.00
Adjustments for increase (decrease) in trade payables, current	(7,321.27)
Adjustments for increase (decrease) in trade payables, non-current	0.00
Adjustments for increase (decrease) in other current liabilities	0.00
Adjustments for increase (decrease) in other non-current liabilities	0.00
Adjustments for depreciation and amortisation expense	1,755.55
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0.00
Adjustments for provisions, current	(684.95)
Adjustments for provisions, non-current	0.00
Adjustments for other financial liabilities, current	(0.55)
Adjustments for other financial liabilities, non-current	0.00
Adjustments for unrealised foreign exchange losses gains	(1,089.11)
Adjustments for dividend income	0.00
Adjustments for interest income	516.60
Adjustments for share-based payments	0.00
Adjustments for fair value losses (gains)	0.00
Adjustments for undistributed profits of associates	0.00
Other adjustments for which cash effects are investing or financing cash flow	(839.11)
Other adjustments to reconcile profit (loss)	52.79
Other adjustments for non-cash items	0.00

	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
	<b>Total adjustments for reconcile profit (loss)</b>	(214.00)
	<b>Net cash flows from (used in) operations</b>	823.63
	Dividends received	0.00
	Interest paid	0.00
	Interest received	0.00
	Income taxes paid (refund)	(327.33)
	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) operating activities</b>	1,150.96
<b>3</b>	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0.00
	Cash flows used in obtaining control of subsidiaries or other businesses	0.00
	Other cash receipts from sales of equity or debt instruments of other entities	0.00
	Other cash payments to acquire equity or debt instruments of other entities	0.00
	Other cash receipts from sales of interests in joint ventures	0.00
	Other cash payments to acquire interests in joint ventures	0.00
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
	Proceeds from sales of property, plant and equipment	0.00
	Purchase of property, plant and equipment	15,875.11
	Proceeds from sales of investment property	896.62
	Purchase of investment property	0.00
	Proceeds from sales of intangible assets	0.00
	Purchase of intangible assets	0.00
	Proceeds from sales of intangible assets under development	0.00
	Purchase of intangible assets under development	0.00
	Proceeds from sales of goodwill	0.00
	Purchase of goodwill	0.00
	Proceeds from biological assets other than bearer plants	0.00
	Purchase of biological assets other than bearer plants	0.00
	Proceeds from government grants	0.00
	Proceeds from sales of other long-term assets	0.00
	Purchase of other long-term assets	0.00
	Cash advances and loans made to other parties	0.00
	Cash receipts from repayment of advances and loans made to other parties	0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
	Dividends received	0.00
	Interest received	713.65
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	5,200.96
	<b>Net cash flows from (used in) investing activities</b>	(9,063.88)
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0.00

	Payments from changes in ownership interests in subsidiaries	0.00
	Proceeds from issuing shares	0.00
	Proceeds from issuing other equity instruments	0.00
	Payments to acquire or redeem entity's shares	0.00
	Payments of other equity instruments	0.00
	Proceeds from exercise of stock options	0.00
	Proceeds from issuing debentures notes bonds etc	0.00
	Proceeds from borrowings	10,127.04
	Repayments of borrowings	0.00
	Payments of lease liabilities	0.00
	Dividends paid	0.00
	Interest paid	126.08
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) financing activities</b>	<b>10,000.96</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>2,088.04</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0.00
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>2,088.04</b>
	<b>Cash and cash equivalents cash flow statement at beginning of period</b>	<b>2,110.68</b>
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>4,198.72</b>

## Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the auditor		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditor Comment on (i) or (ii) above
No records available							